Archives
-
CDK4/6–BET Synergy in Pancreatic Cancer Wnt Signaling
2026-09-15
The 2025 reference study shows that palbociclib can suppress pancreatic tumor-cell proliferation while paradoxically increasing migration, invasion, and epithelial-to-mesenchymal transition. Its central innovation is the use of BET inhibition to counter this adaptive response through GSK3β-mediated Wnt/β-catenin and TGF-β/Smad pathway regulation, producing stronger antitumor activity in vitro and in an orthotopic model.
-
BI 2536: A Better Way to Read PLK1 Inhibition
2026-09-14
BI 2536 is a selective PLK1 inhibitor for dissecting mitotic arrest, growth suppression, and apoptosis in cancer models. This article applies a two-axis assay framework to improve interpretation of BI 2536 responses from cultured cells to tumor xenograft models.
-
Ruxolitinib JAK1/2 Research Workflows
2026-09-14
Build reproducible Ruxolitinib assays by connecting phospho-STAT readouts, progenitor-cell growth, and immune-cell profiling. This practical workflow also adapts the reference study’s multi-readout design without confusing TLR4 biology with direct JAK1/2 inhibition.
-
Prestained Protein Marker for LARP1 Blot Workflows
2026-09-13
Use a Triple color protein ladder to connect ribosome-fractionation experiments with confident SDS-PAGE sizing, transfer checks, and fluorescent imaging. This workflow shows how an EDTA-free marker supports LARP1 research without overstating what a molecular-weight standard can prove.
-
BBB Permeability Modeling with Lysosomal Correction
2026-09-12
The 2025 Drug Delivery study developed a high-throughput surrogate blood-brain barrier model by pairing LLC-PK1-MOCK and LLC-PK1-MDR1 cells with bidirectional Transwell transport measurements. Its lysosomal-trapping correction improved interpretation of low-recovery compounds and strengthened the relationship between in vitro permeability and in vivo unbound brain distribution.
-
L-Threonine: Metabolism and ALP Assays
2026-09-11
L-Threonine is an essential proteinogenic amino acid that links protein biosynthesis with central carbon metabolism. Its role in alkaline phosphatase research is interpretive rather than pharmacological: the cited metal-free nanozyme assay measures ALP through pyrophosphate hydrolysis, not through L-Threonine inhibition.
-
PD 173074: FGFR1 and VEGFR2 Research Guide
2026-09-11
PD 173074, also written PD-173074, is an ATP-competitive FGFR1 and VEGFR2 research inhibitor with nanomolar reported activity. Its structure, angiogenesis inhibition profile, formulation properties, and model-specific use support cancer research and pathway-dissection workflows.
-
Reactive Oxygen Species Assay Kit: ROS Workflow
2026-09-10
Build a reproducible live-cell oxidative stress workflow with the Reactive Oxygen Species Assay Kit and its DCFH-DA fluorescent probe. Use it to map ROS changes in redox-active cancer models, validate ROS-responsive nanotherapies, and distinguish fluorescence shifts from genuine cellular injury.
-
Exosomal HMGB1 in Lupus Nephritis Endothelial Injury
2026-09-10
The reference study identifies podocyte-derived exosomal HMGB1 as a mediator of glomerular endothelial cell injury in lupus nephritis and places TRIM27 downstream of this intercellular signal. Its combination of patient material, cellular perturbation, and mouse-model validation provides a useful framework for dissecting vesicle-mediated mechanisms of proteinuria.
-
Primidone (Mysoline): Research Workflows
2026-09-09
Primidone (Mysoline) is a versatile research probe for TRPM3 channel inhibition, RIPK1 signaling, and selective biochemical counter-screening. This practical guide connects assay design with ALS and adenomyosis models while emphasizing solvent control, concentration selection, and mechanistic interpretation.
-
Leupeptin: Protease Control for TET2 Workflows
2026-09-09
Leupeptin provides reversible, competitive control of serine and cysteine proteases across biochemical, autophagy, and viral assays. This guide connects fresh-solution handling and dose-response design with the TET2 metabolite-binding workflow, while clearly separating validated evidence from practical extensions.
-
THZ1: Covalent CDK7 Inhibitor Guide
2026-09-08
THZ1 is a covalent CDK7 inhibitor that targets CDK7 through irreversible modification of C312 outside the kinase domain. Product-reported activity in T-ALL models and published resistance data support its use for transcription regulation, cancer biology, and mechanism-focused inhibitor studies.
-
TCAIM, OGDH, and Mitochondrial Metabolic Control
2026-09-08
The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that specifically binds native OGDH and promotes its reduction through HSPA9 and LONP1. This work expands the role of mitochondrial proteostasis from protein folding and quality control to selective regulation of a rate-limiting metabolic enzyme, with consequences for OGDH complex activity and carbohydrate catabolism.
-
EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Readout Assays
2026-09-07
EZ Cap Cy5 Firefly Luciferase mRNA combines fluorescent cargo tracking with functional luciferase reporting. This article presents a practical framework for separating delivery, intracellular trafficking, and translation—and connects those assay decisions to emerging MOF-based mRNA delivery research.
-
Clozapine N-oxide: From DREADDs to Circuit Logic
2026-09-07
Clozapine N-oxide (CNO) is more than a DREADDs activator: it is a controlled entry point for connecting GPCR signaling to intrinsic neuronal computation. This guide translates recent PV interneuron research into practical assay design, controls, and interpretation strategies.